Effects of Paclitaxel and Carboplatin Combination on Mechanical Myocardial and Microvascular Functions: A Transthoracic Doppler Echocardiography and Two‐Dimensional Strain Imaging Study

  • Cihan Altin
    Department of Cardiology The University of Baskent Ankara Turkey
  • Leyla Elif Sade
    Department of Cardiology The University of Baskent Ankara Turkey
  • Saadet Demirtas
    Department of Cardiology The University of Baskent Ankara Turkey
  • Emir Karacaglar
    Department of Cardiology The University of Baskent Ankara Turkey
  • Suleyman Kanyilmaz
    Department of Cardiology The University of Baskent Ankara Turkey
  • Vahide Simsek
    Department of Cardiology The University of Baskent Ankara Turkey
  • Ali Ayhan
    Department of Gynecology and Obstetrics The University of Baskent Ankara Turkey
  • Haldun Muderrisoglu
    Department of Cardiology The University of Baskent Ankara Turkey

Abstract

<jats:sec><jats:title>Aim</jats:title><jats:p>Paclitaxel and carboplatin are frequently used chemotherapy drugs in the treatment of gynecologic malignancies. Little is known about their effects on left ventricular mechanical and coronary microvascular functions.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Thirty consecutive patients were prospectively enrolled. Patients underwent transthoracic echocardiography (TTE) before and after chemotherapy, to evaluate left ventricular mechanical functions and coronary flow reserve (<jats:styled-content style="fixed-case">CFR</jats:styled-content>). A comprehensive TTE, tissue Doppler and two‐dimensional (2D) strain imaging were performed and coronary flow velocity was measured at baseline and after dipyridamole infusion. <jats:styled-content style="fixed-case">CFR</jats:styled-content> was calculated as the ratio of hyperemic to baseline diastolic peak flow velocities. Mitral annular velocities by tissue Doppler, peak strain, and systolic strain rate by velocity vector imaging (<jats:styled-content style="fixed-case">VVI</jats:styled-content>) were measured. Baseline measurements were compared with healthy controls (n = 26).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>No patient developed heart failure (HF) symptoms, no significant change occurred in left ventricular ejection fraction or cardiac output and no significant difference was observed in <jats:styled-content style="fixed-case">CFR</jats:styled-content> after chemotherapy. Baseline mean longitudinal peak strain and systolic stain rate were similar between patients and controls: −17.5 ± 2.6% versus −17.6 ± 2.2% (P = NS) and −1.04 ± 0.14/sec versus −1.05 ± 0.12/sec (P = NS). Peak strain and systolic strain rate decreased significantly after chemotherapy (from −17.5 ± 2.6% to −16.2 ± 2.5%, P<jats:italic> </jats:italic><<jats:italic> </jats:italic>0.02; and from −1.05 ± 0.12/sec to −0.96 ± 0.11/sec, P<jats:italic> </jats:italic>=<jats:italic> </jats:italic>0.01, respectively). However, mean longitudinal velocity did not change significantly.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Paclitaxel and carboplatin combination did not impair <jats:styled-content style="fixed-case">CFR</jats:styled-content>; however, this chemotherapy combination could induce subtle impairment in myocardial mechanical function which can be detected by advanced deformation imaging techniques rather than by tissue Doppler imaging or conventional 2D and Doppler echocardiography.</jats:p></jats:sec>

Journal

Citations (1)*help

See more

Report a problem

Back to top